Publications by authors named "G M Liberatore"
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) often requires prolonged ongoing treatment to prevent worsening. The efficacy of rituximab in preventing worsening after the discontinuation of immunoglobulin therapy in CIDP patients was assessed. In this randomized, double-blind, placebo-controlled study, conducted at seven Italian hospitals, CIDP patients under immunoglobulin therapy were assigned to receive either rituximab (1g on days 1, 15, and 180±7) or placebo.
View Article and Find Full Text PDFThis study investigates the management of patients with obstructive sleep apnea (OSA) who have previously undergone palatal surgery and subsequently undergo maxillomandibular advancement (MMA). The research entails a retrospective analysis of phase II MMA cases from 2017 to 2022. Data encompassing demographics, clinical profiles, pre- and post-operative polysomnographic and radiological findings, surgical techniques, and complications were collected.
View Article and Find Full Text PDFProspective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies.
J Neurol Neurosurg Psychiatry
August 2024
Article Synopsis
- A study evaluated the effectiveness of rituximab in 17 CIDP patients who had not responded to at least two traditional immune therapies.* -
- After 6 months, 76.5% of patients showed improvement, with 92.9% maintaining improvements after 12 months, and no patients dropped out due to side effects.* -
- The results indicate rituximab is a potentially safe and effective treatment for CIDP, suggesting further research through controlled trials is warranted.*
Advances in the understanding of cytokines have revolutionized mechanistic treatments for chronic inflammatory and autoimmune diseases, as exemplified by rheumatoid arthritis. We conducted a systematic literature review on the role of cytokines and chemokines in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). Ovid Medline, EMBASE and Web of Science were searched until August 31, 2022 for human studies investigating cytokines levels in CIDP or MMN.
View Article and Find Full Text PDFArticle Synopsis
- The 2021 EAN/PNS guidelines provide detailed clinical criteria to diagnose various variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), despite the lack of research on their treatment impact.
- In a study involving 369 patients from the Italian CIDP database, 66% were diagnosed with different CIDP variants using these new criteria, revealing a distribution of typical and atypical forms.
- The findings indicate that patients with multifocal, distal, and sensory CIDP often experience milder symptoms and may respond differently to steroid treatments compared to those with other variants, underscoring the need for specific guidelines in managing CIDP.